Guardant Health Inc.
Guardant Health Reports Strong Q3 2025 Results and Raises Full-Year Guidance
Summary
Guardant Health, Inc. reported a 39% increase in third-quarter 2025 revenue to $265.2 million, driven by strong performance in Oncology, Screening, and Biopharma & Data segments. The company raised its 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31%. Key highlights include 40% growth in Oncology tests and the expansion of its Shield screening test to include multi-cancer detection. Non-GAAP gross margin improved to 66%, and the company now expects full-year non-GAAP gross margin to be in the range of 64% to 65%.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement